科济药业-B旗下CT0596获中国药监局临床试验许可,针对复发/难治性多发性骨髓瘤

美股速递
Aug 04

科济药业-B(CARSGEN-B)宣布,其创新药物CT0596已获得中国国家药品监督管理局(NMPA)的临床试验默示许可。该药物旨在针对复发/难治性多发性骨髓瘤这一棘手疾病展开治疗探索。这一里程碑式的进展,意味着科济药业在攻克血液肿瘤领域的征程上,又迈出了坚实的一步。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10